Developing treatments for the diseases that are hardest to treat*
We wholly own a platform with the potential for treating a wide range of diseases — from cancers to inflammation-based diseases like arthritis and kidney disease. Endocyte technology is in mid-stage clinical trials.
PLATFORM YIELDS MULTIPLE NEW SMDCs*
|PROGRAM||INDICATION||PHASE||PRECLINICAL||PHASE 1||PHASE 2||PHASE 3|
|Oncology: Small Molecule Drug Conjugates (SMDCs)|
|EC1169 Prostate-specific Membrane Antigen||Prostate Cancer||PHASE 1|
|EC1456 Folate Receptor (FR)||NSCLC||PHASE 1|
|Immuno-Oncology: SMDC and Cell-Based Therapy|
|EC2629 FR-expressing Tumor Associated Macrophages + Tumor Cells||Solid Tumors||PRECLINICAL|
|Chimeric Antigen Receptor (CAR) T-Cell (Multiple FITC Adaptor Molecules)||To Be Determined||PRECLINICAL|
|EC2319 FR-expressing Activated Macrophages||To Be Determined||PRECLINICAL|
|Imaging: Companion Imaging Agents|
|Etarfolatide Folate Receptor||To Be Determined||PHASE 3|
|99mTc -EC0652 Prostate-specific Membrane Antigen||Prostate Cancer||PHASE 1|
Endocyte technology has the potential for broad application
Our technology has the potential to treat the types of cancers found in over 40% of cancer patients worldwide.1 Our lead companion imaging agent and SMDC target the folate receptor, which is frequently expressed in some of the most prevalent, and difficult to treat, solid tumor cancer indications, including non-small cell lung, breast, colorectal, kidney, endometrial, and ovarian cancers.
Using our flexible SMDC technology platform, we are also developing precision therapies for other cancer-cell receptors and diseases. One of our imaging agents, EC0652, is being developed to non-invasively identify tumors that overexpress prostate-specific membrane antigen (PSMA) receptors, and is currently being evaluated in a Phase 1 trial for patients with advanced prostate cancer.
An engine for new drug development
With the advent of an innovative form of delivery, more research and development can focus on new potent cytotoxic drugs.
What’s more, our modular technology is being studied with different drugs or a combination of drugs in a variety of diseases, allowing for potential expansion into lower-expressing cancer indications and other difficult-to-treat diseases.
Our pipeline and the future of precision medicine
Two SMDCs are now in clinical trials: one is a prostate-specific membrane antigen (PSMA)-targeted drug and the other is designed to deliver a potent chemotherapy drug called tubulysin using our second-generation guidance system. Each targeted therapeutic is also paired with an imaging agent that is designed to identify the patients most likely to benefit from treatment.
* The safety and efficacy of these agents have not been established. There is no guarantee that the agents will receive regulatory approval and become commercially available for the uses being investigated.
Reference 1.: Low PS, Kularatne SA. Folate-targeted therapeutic and imaging agents for cancer. Curr Opin Chem Biol. 2009 Jun;13(3):256-262. doi: 10.1016/j.cbpa.2009.03.022. Epub 2009 May 4.